How many drugs treat Sedation?

Drug Landscape tracks 5 marketed treatments for Sedation (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/sedation.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Sedation — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sedation (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Sedation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Versed	midazolam	Generic (originally Roche)	Benzodiazepine (short-acting)	Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2	1985-12-20
Versed	Midazolam Hydrochloride	Takeda Pharmaceutical Company Limited	Benzodiazepine	GABA A receptor alpha-5/beta-2/gamma-2	1985-01-01
Valium	diazepam	Generic (originally Roche)	Benzodiazepine [EPC]	Adenosine receptor A3, Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2	1963-11-15
Phenergan	promethazine	Generic (originally Wyeth/Pfizer)	Phenothiazine antihistamine/antiemetic	Aldehyde oxidase, 5-hydroxytryptamine receptor 6, FAD-linked sulfhydryl oxidase ALR	1951-01-01
Byfavo	Byfavo	Chungbuk National University Hospital		GABA A receptor alpha-2/beta-2/gamma-2, GABA A receptor alpha-3/beta-2/gamma-2, GABA A receptor alpha-5/beta-2/gamma-2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Generic (originally Roche) · 2 drugs in Sedation
Chungbuk National University Hospital · 1 drug in Sedation
Generic (originally Wyeth/Pfizer) · 1 drug in Sedation
Takeda Pharmaceutical Company Limited · 1 drug in Sedation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Sedation:

Cite this brief

Drug Landscape (2026). Sedation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/sedation. Accessed 2026-06-10.

Sedation full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing